康莱特注射液联合化疗治疗晚期非小细胞肺癌的效果和安全性评价
|
摘要
目的探讨并观察康莱特注射液联合化疗治疗晚期非小细胞肺癌的效果及安全性。方法选取本院2016年2月至2017年2月共62例晚期肺癌患者为研究对象,根据电脑随机分配的方式将这62例肺癌患者分为对照组和观察组,每组31例。对照组采取单纯性治疗方式,观察组在对照组的基础上结合康莱特注射液进行治疗。对比两组患者的生存率、临床效果。结果观察组患者的治疗疗效以及生存质量等均明显高于对照组,差异有统计学意义(P<0.05)。结论对于晚期肺癌患者采取康莱特注射液联合化疗治疗,能够有效的改善患者的实际情况,提高患者的质量以及减少患者的不良反应率,具有一定的安全性,提高患者的生存率,值得在临床推广并使用。
Objective To explore and observe the efficacy and safety of Kang-Wright injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods In our hospital from February 2016 to February 2017, 62 patients with advanced lung cancer were studied, according to the random distribution of computer, the 62 patients were divided into 31 control group and 31 cases group, the control group adopted simple treatment, the observation group was treated with Kang-Wright injection on the basis of the control group. The survival rate and clinical effect of the two groups were compared. Results The therapeutic efficacy and quality of life of the patients in the observation group were significantly higher than those in the control group, and the difference was statistically significant(P<0.05). Conclusion For patients with advanced lung cancer to take Kang-Wright injection combined with chemotherapy, can effectively improve the actual situation of patients, improve the quality of patients and reduce the adverse reaction rate, has a certain degree of safety, improve the survival rate of patients, it is worth in the clinical promotion and use.
Objective To explore and observe the efficacy and safety of Kang-Wright injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods In our hospital from February 2016 to February 2017, 62 patients with advanced lung cancer were studied, according to the random distribution of computer, the 62 patients were divided into 31 control group and 31 cases group, the control group adopted simple treatment, the observation group was treated with Kang-Wright injection on the basis of the control group. The survival rate and clinical effect of the two groups were compared. Results The therapeutic efficacy and quality of life of the patients in the observation group were significantly higher than those in the control group, and the difference was statistically significant(P<0.05). Conclusion For patients with advanced lung cancer to take Kang-Wright injection combined with chemotherapy, can effectively improve the actual situation of patients, improve the quality of patients and reduce the adverse reaction rate, has a certain degree of safety, improve the survival rate of patients, it is worth in the clinical promotion and use.
引文
[1]李向东,董灵.康莱特注射液联合化疗对晚期非小细胞肺癌生活质量及骨髓抑制的影响[J].河北医学,2016(4):543-545.
[2]付鹏,李翔,王超,等.康莱特注射液在中晚期非小细胞肺癌治疗中的临床应用研究[J].癌症进展,2016,14(3):266-268.
[3]朱佳佳,尤寅骏.康莱特注射液联合GP方案对晚期非小细胞肺癌患者免疫功能的改善作用[J].河南中医,2016,36(11):1943-1945.
[4]龚伟峰,陈学信.康莱特注射液联合化疗治疗晚期非小细胞肺癌的疗效评价[J].医药与保健,2017,25(4):70-71.
[5]鲁小敏,张燕,吉浩明,等.康莱特注射液联合化疗对晚期非小细胞肺癌疗效及免疫功能的影响[J].江苏医药,2016,42(9):1068-1070.
[6]刘坤,杨勇,王羽丰,等.康莱特注射液联合化疗治疗晚期非小细胞肺癌36例临床观察[J].中国民族民间医药,2016,25(9):97-99.
[7]刘雪娇.康莱特联合化疗治疗中晚期非小细胞肺癌临床疗效观察[J].临床军医杂志,2017,45(3):265-268.
[8]李向东,董灵.康菜特注射液联合化疗对晚期非小细胞肺癌生活质量及骨髓抑制的影响[J].河北医学,2016,22(4):543-545.
[2]付鹏,李翔,王超,等.康莱特注射液在中晚期非小细胞肺癌治疗中的临床应用研究[J].癌症进展,2016,14(3):266-268.
[3]朱佳佳,尤寅骏.康莱特注射液联合GP方案对晚期非小细胞肺癌患者免疫功能的改善作用[J].河南中医,2016,36(11):1943-1945.
[4]龚伟峰,陈学信.康莱特注射液联合化疗治疗晚期非小细胞肺癌的疗效评价[J].医药与保健,2017,25(4):70-71.
[5]鲁小敏,张燕,吉浩明,等.康莱特注射液联合化疗对晚期非小细胞肺癌疗效及免疫功能的影响[J].江苏医药,2016,42(9):1068-1070.
[6]刘坤,杨勇,王羽丰,等.康莱特注射液联合化疗治疗晚期非小细胞肺癌36例临床观察[J].中国民族民间医药,2016,25(9):97-99.
[7]刘雪娇.康莱特联合化疗治疗中晚期非小细胞肺癌临床疗效观察[J].临床军医杂志,2017,45(3):265-268.
[8]李向东,董灵.康菜特注射液联合化疗对晚期非小细胞肺癌生活质量及骨髓抑制的影响[J].河北医学,2016,22(4):543-545.